Floatz logo

Tasquinimod

Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

230 Active assets in the Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
Bayer
Phase 4BB

View all 50 →

Same molecule, other indications

Tasquinimod is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →